RENSSELAER, N.Y., Feb 3 (Bernama-GLOBE NEWSWIRE ) — Taconic Biosciences, a global leader in providing drug discovery animal model solutions, expands its premier immuno-oncology portfolio with the launch of the new B2m-NOG mouse model.
Immuno-oncology leverages the body’s immune system to fight cancer, increasing the ability to target the disease. Animal models used in this therapeutic development include special mice, which model human immune system function. Taconic’s immuno-oncology portfolio is built on the CIEA NOG mouse®, a severely immunodeficient mouse with diverse applications based on its improved ability to engraft human cells and tissues. B2m-NOG is an important addition to this portfolio because it significantly extends the study window after human peripheral blood mononuclear (PBMC) cell engraftment, providing more time to assess reactions to target drugs. The extended study window dramatically expands immuno-oncology study types that can be run using the B2m-NOG model compared with more expensive and time-consuming options, such as hematopoietic stem cell-engrafted models. Taconic also offers B2m-NOG mice pre-engrafted with human PBMCs.